Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nona Biosciences (Suzhou) Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The portfolio's prosecution is very focused, with activity limited to 1 distinct examiner and 1 distinct art unit. This suggests that the company is currently advancing a specific biological or pharmaceutical innovation through a narrow technical channel. The presence of only 1 distinct art unit indicates that the technology is classified within a specific niche of the biotechnology sector.
The busiest examiner, MIDDLETON, DANAYA L, is responsible for 1 busiest examiner pending action. Given that the total pending office actions and the busiest examiner pending count are each 1, this examiner handles the company's entire active workload. The presence of only 1 distinct examiner means that the outcome of the portfolio's current prosecution phase depends on the interactions with this official. Practitioners should focus on the examination patterns of MIDDLETON, DANAYA L to gauge the potential for success in this single pending matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIDDLETON, DANAYA L | 1 | 49.5% | +48.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18013523 | MULTISPECIFIC BINDING PROTEIN OF IMMUNE CELL ENGAGER, PREPARATION THEREFOR AND APPLICATION THEREOF | MIDDLETON, DANAYA L | 27d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18013523 | MULTISPECIFIC BINDING PROTEIN OF IMMUNE CELL ENGAGER, PREPARATION THEREFOR AND APPLICATION THEREOF | MIDDLETON, DANAYA L | 27d |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18013523 | MULTISPECIFIC BINDING PROTEIN OF IMMUNE CELL ENGAGER, PREPARATION THEREFOR AND APPLICATION THEREOF | MIDDLETON, DANAYA L | 1674 | §103§112Other | Final Rejection | 27d | Pending | Dec 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNona Biosciences (Suzhou) Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Danaya L Middleton has the most, with 1 of Nona Biosciences (Suzhou) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
